Saturday 11 May 2019
CSL Behring, a global biotherapeutics leader, has inaugurated its regional headquarters at Dubai Science Park (DSP), a holistic science-focused business community dedicated to the development of the local healthcare sector. The opening of the new office will strengthen the company’s presence in the Middle East and Africa (MEA) region.
Biotherapeutics is one of the fastest-growing segments of the pharmaceutical industry. Its annual growth is estimated at more than 10 percent, compared to conventional pharmaceuticals at 7 percent. The UAE’s positive investment climate and its attractiveness as a hub for pharma and healthcare activities has encouraged multiple international companies to set up locally, especially in niche industries.
CSL Behring is a leader in the USD 24 billion plasma market. The company is researching therapies to reduce the risk of early recurrent cardiovascular events, improve the outcomes of organ transplants, and treat sickle cell disease, β-thalassemia, and autoimmune diseases.
With global operational headquarters based in Pennsylvania, USA, CSL Behring owns one of the world’s largest plasma collection networks and operates six research facilities around the world. As part of its growth strategy, the company has placed a strong emphasis on expansion in emerging markets. CSL Behring’s foray into the MEA region is expected to create employment opportunities for local talent.
Currently home to over 350 business partners, DSP provides an environment for science companies to set up, grow, and flourish. The business community aims to contribute to consolidating Dubai’s position as a preferred destination for local and international companies within the science sector.